These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32814590)

  • 1. The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia.
    Shen CF; Wang SM; Chi H; Huang YC; Huang LM; Huang YC; Lin HC; Ho YH; Hsiung CA; Liu CC;
    J Biomed Sci; 2020 Aug; 27(1):88. PubMed ID: 32814590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
    Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
    Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules.
    Lee HY; Hsieh YC; Liu CC; Huang YC; Chang KY; Chi H; Chang LY; Huang YC; Huang LM;
    J Microbiol Immunol Infect; 2018 Apr; 51(2):199-206. PubMed ID: 29021105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
    Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
    Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
    van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
    Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
    Syrogiannopoulos GA; Michoula AN; Tsimitselis G; Vassiou K; Chryssanthopoulou DC; Grivea IN
    Infect Dis (Lond); 2016 Oct; 48(10):749-53. PubMed ID: 27320108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
    Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
    Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.
    Cohen R; Biscardi S; Levy C
    Hum Vaccin Immunother; 2016; 12(2):277-84. PubMed ID: 26905678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.